Carregant...
Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
OBJECTIVE: Romidepsin (FK228) was recently approved by the FDA for the treatment of cutaneous and peripheral T cell lymphoma. We have shown in vitro efficacy of FK228 in ovarian cancer. Here, our goal was to evaluate FK228 combined with cisplatin in ovarian cancer in vitro and in vivo. METHODS: Ovar...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3541411/ https://ncbi.nlm.nih.gov/pubmed/23010348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.09.016 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|